Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician's choice (TPC) Meeting Abstract


Authors: Lorusso, D.; Colombo, N.; Herraez, A. C.; Santin, A. D.; Colomba, E.; Miller, D. S.; Fujiwara, K.; Pignata, S.; Baron-Hay, S. E.; Ray-Coquard, I. L.; Shapira-Frommer, R.; Kim, Y. M.; McCormack, M.; Massaad, R.; Nguyen, A. M.; Zhao, Q.; McKenzie, J.; Prabhu, V. S.; Makker, V.
Abstract Title: Time to deterioration in quality of life in patients (pts) with advanced endometrial cancer (aEC) treated with lenvatinib plus pembrolizumab (L+P) or treatment of physician's choice (TPC)
Meeting Title: ESMO Gynaecological Cancers Congress 2022
Journal Title: Annals of Oncology
Volume: 33
Issue: Suppl. 5
Meeting Dates: 2022 Jun 17-18
Meeting Location: Valencia, Spain
ISSN: 0923-7534
Publisher: Oxford University Press  
Date Published: 2022-06-01
Start Page: S391
End Page: S392
Language: English
ACCESSION: WOS:000814982500021
DOI: 10.1016/j.annonc.2022.04.038
PROVIDER: wos
Notes: Meeting Abstract: 20MO -- Source: Wos
Altmetric
Citation Impact
BMJ Impact Analytics
MSK Authors
  1. Vicky Makker
    265 Makker